Top Page
Monash IVF Group Ltd
(Sydney:MVF)
Monash IVF Group Ltd (MVF) vs. iShares MSCI Australia ETF (EWA)
Monash IVF Group Ltd Business Overview & Revenue Model
Monash IVF Group Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 271.92M | 271.92M | 254.96M | 213.59M | 192.29M | 183.60M |
| Gross Profit | 90.31M | 90.31M | 85.50M | 63.41M | 57.22M | 57.66M |
| EBITDA | 53.01M | 53.01M | 10.78M | 48.49M | 43.16M | 51.21M |
| Net Income | 25.01M | 25.01M | -6.53M | 21.84M | 18.41M | 25.15M |
Balance Sheet | ||||||
| Total Assets | 492.61M | 492.61M | 508.47M | 421.89M | 387.10M | 356.17M |
| Cash, Cash Equivalents and Short-Term Investments | 9.43M | 9.43M | 11.33M | 8.01M | 7.87M | 8.76M |
| Total Debt | 180.31M | 180.31M | 135.37M | 100.04M | 77.23M | 45.99M |
| Total Liabilities | 242.19M | 242.19M | 261.81M | 146.82M | 117.20M | 87.73M |
| Stockholders Equity | 246.28M | 246.28M | 241.91M | 273.20M | 267.92M | 266.19M |
Cash Flow | ||||||
| Free Cash Flow | 468.00K | 468.00K | 31.70M | 10.16M | 19.51M | 33.30M |
| Operating Cash Flow | 12.90M | 12.90M | 52.52M | 37.95M | 31.28M | 43.25M |
| Investing Cash Flow | -17.43M | -17.43M | -38.80M | -40.51M | -15.16M | -11.21M |
| Financing Cash Flow | 6.68M | 2.67M | -10.39M | 1.51M | -17.02M | -38.35M |
Monash IVF Group Ltd Technical Analysis
Monash IVF Group Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$520.92M | 15.80 | 18.59% | 4.60% | 6.73% | 37.16% | |
67 Neutral | AU$292.23M | 11.68 | 10.25% | 6.22% | 6.65% | ― | |
64 Neutral | AU$11.07B | 20.94 | 6.32% | 4.69% | 9.44% | -0.37% | |
55 Neutral | AU$947.23M | 167.11 | 0.94% | 2.65% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$707.98M | -1.35 | -67.21% | ― | -23.02% | 33.11% |
Monash IVF Group Ltd Corporate Events
Monash IVF Group Ltd has announced that Dr. Victoria Atkinson will commence her role as Managing Director and Chief Executive Officer on 5 January 2026. This leadership change is expected to impact the company’s operations and strategic direction, potentially influencing its market positioning in the assisted reproductive services industry.
The most recent analyst rating on (AU:MVF) stock is a Hold with a A$0.94 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group has released its Sustainability Report for 2025, highlighting its commitment to environmental, social, and governance (ESG) principles. The report outlines the company’s strategies for integrating ESG into its operations, emphasizing the importance of sustainability in its business model and its impact on communities and patients. This initiative reflects Monash IVF Group’s dedication to responsible governance and its efforts to enhance its industry positioning by addressing key sustainability challenges.
The most recent analyst rating on (AU:MVF) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Ltd has announced that Regal Funds Management Pty Ltd, along with its associates, has ceased to be a substantial holder in the company. This change in substantial holding reflects a series of transactions involving buying and selling of shares, ultimately impacting the voting securities of the company. The announcement may influence the company’s market perception and stakeholder interests as it indicates a shift in the composition of its major shareholders.
The most recent analyst rating on (AU:MVF) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Ltd announced the appointment of Dwayne Crombie as a director, effective from November 24, 2025. The initial director’s interest notice reveals that Crombie currently holds no relevant interests in the company’s securities, indicating a neutral impact on the company’s operations and market positioning.
The most recent analyst rating on (AU:MVF) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Limited has rejected a non-binding indicative proposal from a consortium led by Genesis Capital and WHSP Holdings to acquire 100% of its shares. The board determined that the offer, priced at $0.80 per share, undervalues the company and is not in the best interest of shareholders. The proposal included conditions such as exclusive due diligence and negotiation of transaction documentation, but the board found the offer to be opportunistic and lacking in value compared to similar market transactions. Monash IVF remains open to considering future proposals that provide compelling value for its shareholders.
The most recent analyst rating on (AU:MVF) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Ltd has announced the issuance of 921,331 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move reflects the company’s strategy to incentivize its workforce, potentially impacting its operational efficiency and aligning employee interests with company performance, thereby strengthening its position in the competitive fertility services market.
The most recent analyst rating on (AU:MVF) stock is a Buy with a A$0.94 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Ltd held its Annual General Meeting on November 20, 2025, where all proposed resolutions were passed by a poll. Key resolutions included the adoption of the remuneration report and the re-election of directors, Mr. Richard Davis and Ms. Zita Peach, indicating strong shareholder support and stability in the company’s governance.
The most recent analyst rating on (AU:MVF) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Ltd’s 2025 Annual General Meeting presentation highlighted the company’s current activities and provided insights into potential future developments. The presentation included forward-looking statements, emphasizing the inherent uncertainties and risks in the industry, and discussed non-IFRS financial measures used to assess business performance.
The most recent analyst rating on (AU:MVF) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group reported a 6.7% increase in revenue and a 5.6% rise in underlying EBITDA for FY25, despite facing challenges such as a softened fertility sector and adverse incidents at two clinics. The company has implemented enhanced safety protocols and conducted an independent review to address these issues. Although no final dividend was declared for FY25 due to settlement payments and softer trading conditions, the company plans to resume dividends in FY26. Monash IVF is undergoing leadership changes, with Dr. Victoria Atkinson set to become the new CEO in May 2026, and is focusing on governance and sustainability practices to ensure long-term growth and value creation.
The most recent analyst rating on (AU:MVF) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Ltd has appointed Dr. Victoria Atkinson as the new Managing Director and CEO, effective from May 18, 2026. Dr. Atkinson brings over 30 years of experience in healthcare leadership, previously serving as Chief Medical Officer at Healthscope. Her appointment is expected to enhance the company’s focus on clinical and financial strategies, benefiting its stakeholders, including patients and doctors. The company is also in the process of finding a new Chief Financial Officer as Mr. Andrew MacLachlan concludes his interim role.
The most recent analyst rating on (AU:MVF) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Ltd has appointed Dr. Dwayne Crombie as an Independent Non-Executive Director, effective from 24 November 2025. Dr. Crombie brings extensive experience from his career in healthcare across New Zealand and Australia, including senior roles at Bupa and governance positions in healthcare organizations. His appointment is expected to enhance the strategic capabilities of the Monash IVF Group Board, potentially impacting the company’s operations and positioning within the healthcare industry.
The most recent analyst rating on (AU:MVF) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
Monash IVF Group Ltd has announced its 2025 Annual General Meeting (AGM), scheduled for November 20, 2025, which will be held as a hybrid event allowing both in-person and virtual participation. The AGM documents, including the Notice of Meeting and Proxy Form, are available on the company’s website, and shareholders are encouraged to submit questions in advance to facilitate a comprehensive discussion during the meeting.
The most recent analyst rating on (AU:MVF) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.